CMS Finalizes Reimbursement Cuts for 340B Hospitals
In a striking blow to 340B hospitals, the Department of Health and Human Services, the Centers for Medicare and Medicaid Services (CMS) published a latest outpatient Medicare Payment System Prospective (OPPS) rule adopting its previous proposal to significantly reduce Medicare reimbursement for separately payable ambulatory drugs purchased by hospitals as part of of program 340B. The final rule confirms that CMS will drop the average sales price (ASP) refund rate plus 6 percent to ASP minus 22.5 percent. The payment changes are to take effect January 1, 2018.
Citing the strong growth of vendor participation in the 340B program and the increase in prices of Medicare Part B-administered drugs to inpatients, the stated goal of CMS is to align the Medicare payment on the amounts spent by hospitals to acquire these drugs. CMS relied on a report from the Medicare Payment Advisory Board (MedPAC) from May 2015 to Congress to determine the new formula. While MedPAC estimated that the ASP less than 22.5 percent that CMS ultimately adopted was the "lower limit of the average reduction" on drugs paid under OPPS Medicare, MedPAC March 2016 Report to Congress recommended a reduction of payment to ASP less 10%, which would have allowed 340B hospitals to realize, on average, a financial benefit to participate in the 340B program.
The financial impact of changes to 340B hospitals
The OPPS changes will have a significant impact on 340B participating hospitals. CMS estimates that the change will result in a $ 1.6 billion reduction in OPPS payments to 340B hospitals for drugs payable separately – an additional estimated reduction of $ 700 million on the estimated $ 900 million rule proposed. While CMS had asked for feedback on how to redistribute savings to target hospitals that treat low-income patients, the final rule instead redistributes the amounts saved by 340B payment reductions by increasing OPPS payments for non-fee-based services. medicated
The CMS exempts single rural community hospitals, children's hospitals and anti-cancer hospitals exempted from SPA from the application of new drug payment reductions for the 2018 calendar year; they will continue to be paid to ASP + 6%. Exempt hospitals will have to report the use of 340B to Medicare for information and follow-up purposes.
Medicare payment changes are likely to be challenged in court by one or more stakeholder groups, including the American Hospital Association . In comments submitted on the proposed rule, several groups argued that CMS did not have the authority to implement such payment changes or reduce 340B hospitals for discounts, and could not otherwise contradict the Intention and scope of the 340B program without further action by Congress. These challenges will likely come before the courts as CMS implements the new rule and Congress continues to debate the future of the 340B program.
No impact on outpatient ambulatory hospital services
Changes to Medicare reimbursement also create new incentives for out-of-campus hospital outpatient services (HOPDs). Since 1 January 2017 new off-campus hospital ambulatory services that do not fall under one exception (non-exempt HOPD) are not eligible for payment under the OPPS, and instead benefit a reduced refund rate. CMS has confirmed in the final rule that new payment reductions for 340B drugs will not be applied to non-exempt HOPDs, as their drugs are not reimbursed under OPPS. As a result, the use of 340B drugs by a non-HOPD exception will not have an impact on the Medicare reimbursement of the HOPD.
Challenges of Implementation
In light of the new rule, 340B hospitals should be preparing to come into compliance, which will require the use of a new modifier on every drug billed to Medicare OPPS that was purchased in the framework of the 340B program. In some cases, this will require greater coordination between the hospital's billing and pharmacy divisions to ensure that the modifier is applied accurately.
We will continue to monitor program 340B and we will keep you informed of any other changes that may occur.
This blog is made available by Foley & Lardner LLP ("Foley" or "the Firm") for informational purposes only. It is not intended to convey the legal position of the firm on behalf of a client, nor to provide specific legal advice. The opinions expressed in this article do not necessarily reflect those of Foley & Lardner LLP, its partners or customers. As a result, do not act on this information without seeking the advice of an authorized lawyer.
This blog is not meant to create, and the receipt of it does not constitute, a lawyer-client relationship. Communicating with Foley through this website via email, blog post or otherwise, does not create an attorney-client relationship for any legal matter. Therefore, any communication or material that you transmit to Foley through this blog, whether by email, blog or otherwise, will not be considered confidential or proprietary.
The information on this blog is published "IN THE STATE" and is not guaranteed to be complete, accurate and up-to-date. Foley makes no representations or warranties of any kind, express or implied, as to the operation or content of the site. Foley expressly disclaims all other warranties, warranties, conditions and representations of any kind, express or implied, arising from any law, law, commercial or other use, including any implied warranties of merchantability, fitness for a particular purpose particular, title and offense. In no event shall Foley or any of its partners, officers, employees, agents or affiliates be liable, directly or indirectly, under any theory of law (contract, tort, negligence or otherwise) , for you or any other person, for any claim, loss or damage, direct, indirect special, incidental, punitive or consequential, resulting or occasioned by the creation, use or trust on this site (including information and other content) or any third party website or the information, resources or materials accessed through these websites.
In some jurisdictions, the content of this blog may be considered an advertising advocate. If applicable, please note that previous results do not guarantee a similar result. The photographs are for dramatic purposes only and may include models. Similarities do not necessarily imply the current status of client, partnership or employee.